Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 16

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 16
---
 CEO of Izana Bioscience since 2017 as well as the Co-Founder of Pathios Therapeutics. Dr. Sidhu has broad expertise covering various topics in the life sciences industry. Prior to these companies, he advised many large international pharmaceutical companies as a management consultant at McKinsey & Co, where he primarily focused on Pharmaceutical R&D and Portfolio Strategy. Dr. Sidhu gained medical experience during his time in Cardiology and General Surgery after graduating from the Oxford Medical School. We believe Dr. Sidhu’s extensive operational and investment experience in the life sciences industry gives him the qualifications, attributes and skills to serve as a director. Robert Lisicki has served as Chief Executive Officer and a director since April 2024 and was previously our President and Chief Operating Officer since January 2024. Mr. Lisicki is an experienced executive leader with a career spanning 30 years in the biopharmaceutical industry. Mr. Lisicki has been serving on the board of Cadrenal Therapeutics, Inc. since July 2023. He previously served as the Chief Executive Officer and a member of the board of directors of InCarda Therapeutics (“InCarda”) from October 2022 to April 2023, where he remained as a consultant until June 2023. Prior to InCarda, Mr. Lisicki served as the Chief Commercial Officer at Arena Pharmaceuticals, Inc. (“Arena”) from October 2018 to March 2022, a prominent biopharmaceutical company acquired by Pfizer for $6.7 billion in 2022. At Arena, Mr. Lisicki had accountability for building the company’s global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8.0 billion. Prior to Arena, Mr. Lisicki served as Vice President and General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this dual role, he led both commercial and developmental initiatives. His career also includes serving as a member of the boards of CorHepta Therapeutics from May 2023 to January 2025 and Adiso Therapeutics from October 2023 to August 2024 and senior leadership roles as Chief Customer Officer of Daiichi Sankyo, Inc. from August 2014 to April 2018, and Vice President of Amgen from July 2005 to August 2014, with his initial experience in sales and marketing at The Janssen Pharmaceutical Companies of Johnson & Johnson from March 1995 to June 200